Dmk Pharmaceuticals
(OTC) ADMP
Dmk Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$12.67M
Net Income (TTM)
$11.56M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
ADMP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Dmk Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
12
CEO
David J. Marguglio
Headquarters
San Diego, CA 92130, US
ADMP Financials
Key Financial Metrics (TTM)
Gross Margin
-61%
Operating Margin
-5%
Net Income Margin
-6%
Return on Equity
-2%
Return on Capital
54%
Return on Assets
-2%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$1.43M
Operating Income
$25.06M
EBITDA
$1.16B
Operating Cash Flow
$25.90M
Capital Expenditure
$680.42K
Free Cash Flow
$26.58M
Cash & ST Invst.
$1.08M
Total Debt
$342.56K
Dmk Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$9.06M
+501.9%
Gross Profit
$9.06M
+6486.1%
Gross Margin
100.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
11
N/A
Net Income
$348.20K
+107.9%
EBITDA
$3.27M
+16.9%
Quarterly Fundamentals
Net Cash
$6.60M
+232.0%
Accounts Receivable
$0.00
-100.0%
Inventory
$662.96K
-39.3%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$63.21K
-82.9%
Return on Assets
-2.42%
N/A
Return on Invested Capital
53.89%
N/A
Free Cash Flow
$2.57M
+74.9%
Operating Cash Flow
$2.57M
+74.0%